This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read DURECT’s 8K filing here.
DURECT Company Profile
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.
See Also
- Five stocks we like better than DURECT
- Technology Stocks Explained: Here’s What to Know About Tech
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- Top Biotech Stocks: Exploring Innovation Opportunities
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- What is a Stock Market Index and How Do You Use Them?
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
